Solventum Corp (NYSE:SOLV) shares are rebounding on Thursday after activist investor Trian Fund Management released a sharply worded open letter criticizing the company’s post‑spin performance and urging the board to take immediate steps to unlock shareholder value.
- Solventum stock is gaining positive traction. What’s driving SOLV shares up?
With Trian controlling nearly 5% of Solventum’s stock, the firm’s public pressure campaign is drawing investor attention and fueling expectations for strategic changes.
Solventum has been “significantly under‑managed” since separating from 3M and that the spin‑out has benefited executives far more than shareholders.
According to Trian, management took one of the largest performance resets of any U.S. spin‑off in the past decade, wiping out $13 billion in shareholder value relative to the $25 billion market cap analysts expected at the time of separation. The firm also highlighted that Solventum’s CEO has received more than $80 million in compensation in just over two years, despite the company generating no shareholder return and holding a market cap of only $12 billion.
What Trian Is Demanding
In its letter, Trian said the board has not taken meaningful steps to improve performance or add independent shareholder representation, despite repeated outreach. The firm said it has heard similar frustrations from other large shareholders in recent weeks.
Trian outlined three actions it believes Solventum should take immediately. First, the company should right‑size overhead costs, improve productivity, and reinvest in growth to return to the performance levels it achieved while still part of 3M. Second, Solventum should simplify its portfolio by divesting non‑core assets, starting with the separation of the Health Information Systems business. Third, the firm urged the company to improve capital allocation by prioritizing share repurchases at current valuation levels.
Solventum’s Chart: Stabilization Attempt, Not A Victory Lap
Technically, Solventum is still in “repair mode.” It’s sitting in the lower half of its 52-week range after printing its 52-week low in April, which keeps the longer-term setup cautious even as the tape improves.
The near-term picture is trying to firm up: the stock is trading 0.3% above its 20-day simple moving average (SMA), but it remains 9.2% below its 100-day SMA, a classic “short-term stabilization, intermediate-term pressure” math. The moving-average stack reinforces the point: the 20-day SMA is below the 50-day SMA, and the death cross in March (50-day SMA below the 200-day SMA) is the market’s way of reminding investors the earlier trend broke for a reason.
Still, momentum is attempting to turn. The moving average convergence divergence (MACD) is above its signal line, a subtle nod toward improving upside momentum versus the prior downswing. Over the last 12 months, the stock is up 1.98%, which reads less like a trend and more like a choppy holding pattern, exactly why traders keep one eye on the April swing low and the other on whether rebounds can stick.
The levels are clean and, in this environment, likely to matter:
- Key Resistance: $69.00
- Key Support: $62.50
If Solventum can’t clear $69.00 with follow-through, the market’s “risk-on” generosity can fade quickly. And if $62.50 gives way, the stabilization narrative turns back into damage control.
SOLV Shares Are Gaining
SOLV Price Action: Solventum shares were up 1.93% at $67.77 at the time of publication on Thursday, according to Benzinga Pro.
Image: Shutterstock
Recent Comments